Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 287 participants.

Also called NCT03349684

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 287 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03349684
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03349684. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-05 (actual); primary completion 2019-08-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Acarbose
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03349684
Content hash
d1f5b6997eebb9f6767ca694775bc9ba97b522d05df2aea30236413bade445dd